Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial

View ORCID ProfileRaches Ella, Siddarth Reddy, William Blackwelder, Varsha Potdar, Pragya Yadav, Vamshi Sarangi, Vinay Kumar Aileni, Suman Kanungo, Sanjay Rai, Prabhakar Reddy, Savitha Verma, Chandramani Singh, Sagar Redkar, Satyajit Mohapatra, Anil Pandey, Pajanivel Ranganadin, Raghavendra Gumashta, Manish Multani, Shameem Mohammad, Parul Bhatt, Laxmi Kumari, Gajanan Sapkal, Nivedita Gupta, Priya Abraham, Samiran Panda, Sai Prasad, Balram Bhargava, Krishna Ella, Krishna Mohan Vadrevu, the COVAXIN Study Group
doi: https://doi.org/10.1101/2021.06.30.21259439
Raches Ella
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Raches Ella
  • For correspondence: rachesella{at}gmail.com
Siddarth Reddy
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Blackwelder
2WB Statistical Consulting LLC, Bethesda, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Varsha Potdar
3Indian Council of Medical Research-National Institute of Virology, Pune, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pragya Yadav
3Indian Council of Medical Research-National Institute of Virology, Pune, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vamshi Sarangi
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vinay Kumar Aileni
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suman Kanungo
4Indian Council of Medical Research-National Institute of Cholera and Enteric Diseases, Kolkatta, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjay Rai
5All India Institute of Medical Sciences, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Prabhakar Reddy
6Nizams Institute of Medical Sciences, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Savitha Verma
7Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chandramani Singh
8All India Institute of Medical Sciences, Patna, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sagar Redkar
9Redkar Hospital, Panjim, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satyajit Mohapatra
10SRM Hospital and Research Centre, Chennai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anil Pandey
11ESIC Medical College and Hospital, Faridabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pajanivel Ranganadin
12Mahatma Gandhi Medical College & Research Institute, Pondicherry, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raghavendra Gumashta
13People’s University, Bhopal, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manish Multani
14Rahate Surgical Hospital, Nagpur, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shameem Mohammad
15Aligarh Muslim University, Aligarh, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Parul Bhatt
16GMERS Medical College and Civil Hospital, Ahmedabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laxmi Kumari
17Government Fever Hospital, Guntur, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gajanan Sapkal
3Indian Council of Medical Research-National Institute of Virology, Pune, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nivedita Gupta
18Indian Council of Medical Research, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Priya Abraham
3Indian Council of Medical Research-National Institute of Virology, Pune, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samiran Panda
18Indian Council of Medical Research, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sai Prasad
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Balram Bhargava
17Government Fever Hospital, Guntur, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krishna Ella
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krishna Mohan Vadrevu
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background We report the clinical efficacy against COVID-19 infection of BBV152, a whole-virion inactivated SARS-CoV-2 vaccine formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG).

Methods We did a double-blind, randomised, multicentre, phase 3 clinical trial in 25 Indian hospitals to evaluate the efficacy, safety, and immunological lot consistency of BBV152. Healthy adults (age 18–98 years) randomised 1:1 using a computer-generated randomisation scheme received two intramuscular doses of vaccine or placebo administered four weeks apart. The primary outcome was laboratory-confirmed symptomatic COVID-19, occurring at least 14 days after the second dose. Secondary outcomes were efficacy in sub-groups for age (18–< 60 years and ≥ 60 years) and in participants with pre-existing stable medical conditions. We also evaluated safety, reactogenicity, and consistency of immune responses for three consecutive manufacturing lots.

Findings Between November 16, 2020 and January 7, 2021 we recruited 25,798 participants who were randomised to BBV152 or placebo groups; 24,419 received two doses of BBV152 (n = 12,221) or placebo (n = 12,198). In a case-driven analysis, 130 cases of symptomatic COVID-19 were reported in 16,973 (0·77%) participants with follow-up at least two weeks after the second vaccination; 24 occurred in the vaccine group and 106 in placebo recipients giving an overall vaccine efficacy of 77·8% (95% CI: 65·2–86·4). Sixteen cases, one vaccinee and 15 placebo recipients, met the severe symptomatic COVID-19 case definition giving a vaccine efficacy of 93·4% (57·1–99·8). Efficacy against asymptomatic COVID-19 was 63·6% (29·0–82·4). BBV152 conferred 65·2% (95% CI: 33·1–83·0) protection against the SARS-CoV-2 Variant of Concern, B.1.617.2 (Delta). BBV152 was well tolerated with no clinically or statistically significant differences in the distributions of solicited, unsolicited, or serious adverse events between vaccine and placebo groups. No cases of anaphylaxis or vaccine-related deaths were reported.

Interpretation BBV152 was immunogenic and highly efficacious against symptomatic and asymptomatic COVID-19 variant associated disease, particularly against severe disease in adults. Vaccination was well tolerated with an overall incidence of adverse events observed over a median of 146 days that was lower than that observed with other COVID-19 vaccines.

Funding This work was supported and funded by Bharat Biotech International Limited and partly co-funded by the Indian Council of Medical Research.

Clinicaltrials.gov: NCT04641481

Competing Interest Statement

This work was funded by Bharat Biotech International Limited and cofunded by the Indian Council of Medical Research. RE, KMV, SPr, SRe, VA and V.S. are employees of Bharat Biotech, with no stock options or incentives. Co author, K.E., is the Chairman and Managing Director of Bharat Biotech. WB is an independent statistical development consultant. VP, PY, GS, PA, NG, and BB are employees of The Indian Council of Medical Research. SK, SR, PRe, SV, CS, SR, SM, AP, PRa, RG, MM, SM, PB, and LK were principal investigators representing the study sites.

Clinical Trial

NCT04471519

Funding Statement

This work was supported and funded by Bharat Biotech International Limited and the Indian Council of Medical Research.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

List of ethics oversight bodies is listed in Supplementary Table 1

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Individual participant (de-identified) data will be made available when the trial is complete upon direct request to the corresponding author with an appropriate research proposal. Once such a proposal is approved data will be shared through a secure online platform.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 02, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial
Raches Ella, Siddarth Reddy, William Blackwelder, Varsha Potdar, Pragya Yadav, Vamshi Sarangi, Vinay Kumar Aileni, Suman Kanungo, Sanjay Rai, Prabhakar Reddy, Savitha Verma, Chandramani Singh, Sagar Redkar, Satyajit Mohapatra, Anil Pandey, Pajanivel Ranganadin, Raghavendra Gumashta, Manish Multani, Shameem Mohammad, Parul Bhatt, Laxmi Kumari, Gajanan Sapkal, Nivedita Gupta, Priya Abraham, Samiran Panda, Sai Prasad, Balram Bhargava, Krishna Ella, Krishna Mohan Vadrevu, the COVAXIN Study Group
medRxiv 2021.06.30.21259439; doi: https://doi.org/10.1101/2021.06.30.21259439
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial
Raches Ella, Siddarth Reddy, William Blackwelder, Varsha Potdar, Pragya Yadav, Vamshi Sarangi, Vinay Kumar Aileni, Suman Kanungo, Sanjay Rai, Prabhakar Reddy, Savitha Verma, Chandramani Singh, Sagar Redkar, Satyajit Mohapatra, Anil Pandey, Pajanivel Ranganadin, Raghavendra Gumashta, Manish Multani, Shameem Mohammad, Parul Bhatt, Laxmi Kumari, Gajanan Sapkal, Nivedita Gupta, Priya Abraham, Samiran Panda, Sai Prasad, Balram Bhargava, Krishna Ella, Krishna Mohan Vadrevu, the COVAXIN Study Group
medRxiv 2021.06.30.21259439; doi: https://doi.org/10.1101/2021.06.30.21259439

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (754)
  • Anesthesia (221)
  • Cardiovascular Medicine (3287)
  • Dentistry and Oral Medicine (363)
  • Dermatology (277)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1169)
  • Epidemiology (13355)
  • Forensic Medicine (19)
  • Gastroenterology (898)
  • Genetic and Genomic Medicine (5144)
  • Geriatric Medicine (481)
  • Health Economics (782)
  • Health Informatics (3263)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1189)
  • Hematology (429)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14619)
  • Intensive Care and Critical Care Medicine (912)
  • Medical Education (476)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4916)
  • Nursing (262)
  • Nutrition (725)
  • Obstetrics and Gynecology (882)
  • Occupational and Environmental Health (795)
  • Oncology (2518)
  • Ophthalmology (723)
  • Orthopedics (280)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (542)
  • Pediatrics (1299)
  • Pharmacology and Therapeutics (549)
  • Primary Care Research (556)
  • Psychiatry and Clinical Psychology (4202)
  • Public and Global Health (7495)
  • Radiology and Imaging (1704)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (980)
  • Rheumatology (479)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (547)
  • Toxicology (72)
  • Transplantation (235)
  • Urology (205)